I have been taking Trazodone 50 mg for about 25 years for sleep.

The latter part of this paper mentions Trazodone a lot. It describes it as a serotonin antagonist and reuptake inhibitor. Sort of what, I think, the"miracle/expensive" drug Nuplazid does for PD psychosis. I will be talking to my wife's Dr's about this.

Repurposed drugs targeting eIF2α-P-mediated translational repression prevent neurodegeneration in mice | Brain | Oxford Academic

Trazodone is an antidepressant in the serotonin antagonist and reuptake inhibitor class, which has additional anxiolytic and hypnotic effects. It has been shown to reduce the behavioural and psychological symptoms of dementia (BPSD) in Alzheimer’s disease (Lopez-Pousa et al., 2008) and in FTD (Lebert et al., 2004), but no studies have looked at the progression of neurodegeneration with trazodone treatment. Although its pharmacological actions in humans are not fully understood, it is thought to have more than one mechanism of therapeutic action, making it a multifunctional drug. It is the first antidepressant with a dual mechanism of action involving inhibition of the serotonin transporter (SERT) and antagonism of the serotonin type 2 (5-HT2) receptor, producing its antidepressant effect by blocking SERT, and increasing serotonin concentrations in the brain. Trazodone exerts antagonistic properties against α1- and α2-adrenergic receptors and histamine H1 receptors, with minimal anticholinergic effects (Monti et al., 1986; Stahl, 2009). Trazodone has previously shown benefit in models of Huntington’s disease, where it improved mitochondrial respiratory complex activity (Kumar et al., 2011) and Morris water maze performance (Kumar et al., 2010)